Ana Kusnetzow, Ph.D., is a founding member of Radionetics and serves as Senior Vice President, Biology. Prior, she was a co-founder of Crinetics Pharmaceuticals Inc. and most recently served as Senior Director, Biology where she led the biology group that supported multiple discovery programs. She co-led the Crinetics discovery program that gave rise to the targeted radiotherapeutics platform that is the basis of the Radionetics pipeline. She was concurrently the program leader for a first-in-class ACTH antagonist, CRN04894, for the treatment of diseases caused by excess ACTH (e.g., Cushing’s disease and congenital adrenal hyperplasia). As a co-founder of Crinetics, she established diverse biology capabilities supporting small molecule and biologics drug development from the ground up, culminating in a $40 million Series A and subsequent financings leading to IPO in 2018, and was a significant contributor to the success of the discovery team that nominated several clinical candidates. Prior to this, Dr. Kusnetzow held a scientific position at Neurocrine Biosciences, Inc. Throughout her career, Dr. Kusnetzow has focused on the structural and pharmacologic characterization of G-protein-coupled receptors to aid in drug discovery and development. Dr. Kusnetzow holds a Ph.D. in Chemistry from Syracuse University, as well as a B.S. from Adrian College. She also conducted post-graduate training at the Jules Stein Eye Institute, Geffen School of Medicine at the University of California, Los Angeles.